Community Acquired Infection

ORIGINAL ARTICLE
Year
: 2014  |  Volume : 1  |  Issue : 1  |  Page : 15--20

Serum procalcitonin as a predicting value in severity and prognosis of CAP in sickle cell patients


Sherif Refaat Alsayed1, Samar Marzouk2, Essam Mousa3 
1 Department of Chest, Faculty of Medicine, El Fayoum University, Faiyum, Egypt
2 Department of Biochemistry, Faculty of Medicine, Cairo University, Giza, Egypt
3 Department of Internal Medicine, Faculty of Medicine, Al Azhar Universty, Cairo, Egypt

Correspondence Address:
Sherif Refaat Alsayed
Department of Chest, Faculty of Medicine, El Fayoum University, Faiyum
Egypt

Background: The Pneumonia Severity Index (PSI) and CURB-65 predict outcomes in community acquired pneumonia but have limitations. Materials and Methods: The study evaluated if procalcitonin in community-acquired pneumonia provides prognostic information with the PSI and CURB-65 in sickle cell adult patients. Twenty sickle cell positive adult patients with a clinical and radiographic diagnosis of community acquired pneumonia were scored using PSI and CRUB-65, and measured procalcitonin levels. Results: They were 12 female 60% and 8 males 40%with mean of age 46.0 ΁ 10.26 and were stratified with PSI, CRUB65 and sampled for procalcitonin level for PSI class I (3) patients 15%, class II (10) patients 50%,class III (3) patients 15%, class IV( one) patient 5% & class V (3) patients 15% with mean of 2.55 ΁ 1.276 were CRUB65 0 (2) patients 10% 1 (11) patients 55% two (3) patients 15%, three (4) patients 20%with mean of 1.45 ΁ 0.94 proclacitonin >0.25 (8) patients 40% and >0.50 are (12) patients 60% with mean of 1.098 ΁ 1.346. Conclusion: Procalcitonin levels on admission predict severity of community-acquired pneumonia in sickle cell patients with a similar prognostic accuracy as PSI and CRUB65 and use of procalcitonin as an adjunct to existing rules may offer additional prognostic information in high risk patients as sickle cell positive patients, further studies must address whether adding PCT to risk scores can increase their safe implementation in clinical practice. This was the scope for patients with sickle cell.


How to cite this article:
Alsayed SR, Marzouk S, Mousa E. Serum procalcitonin as a predicting value in severity and prognosis of CAP in sickle cell patients.Community Acquir Infect 2014;1:15-20


How to cite this URL:
Alsayed SR, Marzouk S, Mousa E. Serum procalcitonin as a predicting value in severity and prognosis of CAP in sickle cell patients. Community Acquir Infect [serial online] 2014 [cited 2019 Sep 18 ];1:15-20
Available from: http://www.caijournal.com/article.asp?issn=2225-6482;year=2014;volume=1;issue=1;spage=15;epage=20;aulast=Alsayed;type=0